Transmedics Group Inc reports results for the quarter ended in March

G. Samdani Avatar

·

·







Transmedics Group Inc reports results for the quarter ended in March – Earnings Summary

















XM does not provide services to residents of the United States of America.

Reuters

Transmedics Group Inc reports results for the quarter ended in March – Earnings Summary



Transmedics Group Inc reports results for the quarter ended in March – Earnings Summary
  • Transmedics Group Inc TMDX.OQ reported quarterly adjusted earnings of 35 cents​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -8 cents. The mean expectation of seven analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -33 cents to 11 cents per share.

  • Revenue rose 133.1% to $96.85 million from a year ago; analysts expected $83.78 million.

  • Transmedics Group Inc’s reported EPS for the quarter was 35 cents​.

  • The company reported quarterly net income of $12.2 million.

  • Transmedics Group Inc shares had risen by 31.5% this quarter and gained 23.2% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 77.4% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 6 “strong buy” or “buy,” 1 “hold” and no “sell” or “strong sell.”

  • The average consensus recommendation for the advanced medical equipment & technology peer group is also “buy”

Wall Street’s median 12-month price target for Transmedics Group Inc is $100.00

This summary was machine generated from LSEG data April 30 at 11:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Mar. 31 2024

-0.05

0.35

Beat

Dec. 31 2023

-0.03

0.12

Beat

Sep. 30 2023

-0.16

-0.78

Missed

Jun. 30 2023

-0.13

-0.03

Beat

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.


Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.




Source link

Leave a Reply

Your email address will not be published. Required fields are marked *